VYNE Therapeutics (VYNE) Price & Analysis

Compare

1,865 Followers

VYNE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.33 - $4.30

Previous CloseN/A

Volume117.27K

Average Volume (3M)2.86M

Market Cap

$5.79M

Enterprise Value$17.21M

Total Cash (Recent Filing)$50.27M

Total Debt (Recent Filing)$63.00K

Price to Earnings (P/E)―

Beta2.17

Next Earnings

Nov 06, 2025

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding16,664,892

10 Day Avg. Volume6,944,380

30 Day Avg. Volume2,856,594

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap2.97

Enterprise Value/Revenue28.45

Enterprise Value/Gross Profit28.45

Enterprise Value/Ebitda-0.39

Forecast

1Y Price Target

$1.25

Price Target Upside257.14% Upside

Rating ConsensusHold

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Financial PositionThe company ends this trial in a relatively stable financial position, with approximately $40 million in cash to extend operations or deploy strategically.

Safety ProfileVYN202 showed clean safety and tolerability, with no adverse events associated with BET inhibition, encouraging further development in other serious autoimmune diseases.

Bears Say

Adverse EventsThere was a higher rate of treatment-emergent adverse events for repibresib subjects compared to the vehicle, which contributed to increased discontinuation rates.

Clinical Trial ResultsRepibresib did not meet the primary endpoint or key secondary endpoint in the Phase 2b vitiligo trial, leading to the decision to discontinue treatment in the ongoing extension phase and terminate the trial.

Financial StabilityThe company's cash, cash equivalents, and investments are expected to last approximately 1.1 years at the current burn rate.

VYNE Therapeutics News

VYNE Therapeutics reports Q2 EPS (13c) vs (22c) last year

Reports Q2 revenue $69,000 vs $198,000 last year. “The strength of our recent clinical and preclinical findings for...

9h ago

VYNE

Watch Out! Analysts Have Recently Downgraded These Stocks

As an investor, it is prudent to keep track of stocks that have been downgraded by Wall Street,...

12d ago

AMD

NEO

Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today?

VYNE Therapeutics stock plummeted on Wednesday after a Phase 2b trial missed its primary endpoint. ...

15d ago

VYNE

VYNE Therapeutics downgraded to Neutral from Buy at BTIG

BTIG analyst Julien Harrison downgraded VYNE Therapeutics (VYNE) to Neutral from Buy with no price target after the...

15d ago

VYNE

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Earnings reports and more have the stock market on the move today, and TipRanks has the latest highlights! ...

15d ago

VYNE Therapeutics downgraded at H.C. Wainwright after vitiligo trial miss

H.C. Wainwright downgraded VYNE Therapeutics (VYNE) to Neutral from Buy and removed the firm’s prior $4.50 price target...

15d ago

VYNE

VYNE Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis downgraded VYNE Therapeutics (VYNE) to Neutral from Buy. Published first on TheFly –...

15d ago

VYNE

VYNE says Phase 2B trial with repibresib gel did not meet primary endpoint

VYNE Therapeutics (VYNE) announced topline results from its Phase 2b trial evaluating Repibresib gel in nonsegmental vitiligo. The...

15d ago

VYNE

VYNE Therapeutics: Hold Rating Amid Mixed Clinical Outcomes and Financial Sustainability

LifeSci Capital analyst Rami Katkhuda has maintained their neutral stance on VYNE stock, giving a Hold rating on...

4h ago

VYNE

VYNE Therapeutics Directors Resign Amid Financial Updates

An announcement from VYNE Therapeutics ( ($VYNE) ) is now available. On August 11 and 13, 2025, Christine...

9h ago

VYNE

VYNE Earnings this Week: How Will it Perform?

Vyne Therapeutics Inc (VYNE) is scheduled to report 2nd quarter earnings on 08/08/2025. Regarding Q2 estimates, Wall Street...

8d ago

VYNE

VYNE Therapeutics: Buy Rating Supported by Promising VYN202 Prospects Amidst Challenges

Analyst Stacy Ku of TD Cowen maintained a Buy rating on VYNE Therapeutics, with a price target of...

15d ago

VYNE

VYNE Therapeutics Ends Phase 2b Trial for Repibresib

The latest announcement is out from VYNE Therapeutics ( ($VYNE) ). On July 30, 2025, VYNE Therapeutics announced...

15d ago

VYNE

Promising Developments in VYNE Therapeutics’ Repibresib Gel for Nonsegmental Vitiligo Drive Buy Rating

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on VYNE Therapeutics today and set a price target...

27d ago

VYNE

VYNE FAQ

What was VYNE Therapeutics’s price range in the past 12 months?

VYNE Therapeutics lowest stock price was $0.33 and its highest was $4.30 in the past 12 months.

What is VYNE Therapeutics’s market cap?

VYNE Therapeutics’s market cap is $5.79M.

When is VYNE Therapeutics’s upcoming earnings report date?

VYNE Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 84 days.

How were VYNE Therapeutics’s earnings last quarter?

VYNE Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.223 by $0.093.

Is VYNE Therapeutics overvalued?

According to Wall Street analysts VYNE Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does VYNE Therapeutics pay dividends?

VYNE Therapeutics does not currently pay dividends.

What is VYNE Therapeutics’s EPS estimate?

VYNE Therapeutics’s EPS estimate is -0.2.

How many shares outstanding does VYNE Therapeutics have?

VYNE Therapeutics has 16,664,892 shares outstanding.

What happened to VYNE Therapeutics’s price movement after its last earnings report?

VYNE Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.223. Following the earnings report the stock price went down -5.109%.

Which hedge fund is a major shareholder of VYNE Therapeutics?

Currently, no hedge funds are holding shares in VYNE

VYNE Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-66.15%

Trailing 12-Months

Asset Growth

-38.45%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

VYNE Therapeutics

VYNE Therapeutics (VYNE) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with dermatological, autoimmune, and other inflammatory conditions. The company utilizes its proprietary technology platforms to create novel drug candidates aimed at addressing significant unmet medical needs. VYNE's core products include its leading investigational therapies, which are designed to improve treatment outcomes for patients suffering from chronic skin disorders and related ailments.

VYNE Therapeutics (VYNE) Earnings & Revenues

Historic Earnings Reports

VYNE Stock 12 Month Forecast

Average Price Target

$1.25

▲(257.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.35,0.4769230769230769,0.6038461538461538,0.7307692307692307,0.8576923076923076,0.9846153846153846,1.1115384615384616,1.2384615384615385,1.3653846153846154,1.4923076923076923,1.6192307692307693,1.7461538461538462,1.873076923076923,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.35,0.4192307692307692,0.48846153846153845,0.5576923076923077,0.6269230769230769,0.6961538461538461,0.7653846153846153,0.8346153846153846,0.9038461538461539,0.9730769230769231,1.0423076923076922,1.1115384615384616,1.1807692307692308,{"y":1.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.35,0.36153846153846153,0.3730769230769231,0.3846153846153846,0.39615384615384613,0.4076923076923077,0.41923076923076924,0.4307692307692308,0.4423076923076923,0.45384615384615384,0.4653846153846154,0.4769230769230769,0.4884615384615385,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.92,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >